» Articles » PMID: 21901282

Vitamin D Deficiency As a Risk Factor for Cystic Fibrosis-related Diabetes in the Scandinavian Cystic Fibrosis Nutritional Study

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2011 Sep 9
PMID 21901282
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: Many cystic fibrosis patients are vitamin D-insufficient. Cystic fibrosis-related diabetes is a major complication of cystic fibrosis. The literature suggests that vitamin D might possess certain glucose-lowering properties. We aimed to assess the relationship between vitamin D and cystic fibrosis-related glucose intolerance.

Methods: We enrolled 898 cystic fibrosis patients from Sweden, Norway and Denmark. Vitamin D intake was assessed using a seven-day food record. Serum 25-hydroxyvitamin D (s25OHD) and HbA(1c) were measured, and an OGTT was carried out. Multiple linear and logistic regressions were used for HbA(1c) and cystic fibrosis-related diabetes/OGTT result as outcome variables, respectively. Each model was controlled for country, and for known cystic fibrosis-related diabetes risk factors: age, sex, genotype, liver dysfunction, long-term corticosteroid treatment, and lung and pancreatic function.

Results: Degree of vitamin D insufficiency (OR 1.36; p = 0.032) and s25OHD < 30 nmol/l (OR 1.79; p = 0.042) were significant risk factors for cystic fibrosis-related diabetes. Accordingly, HbA(1c) value was positively associated with s25OHD < 30 nmol/l and < 50 nmol/l, as well as with degree of vitamin D insufficiency (adjusted R (2) = 20.5% and p < 0.05 in all). In subgroup analyses, s25OHD < 30 nmol/l determined the HbA(1c) value in paediatric patients (adjusted R (2) = 20.2%; p = 0.017), but not in adults.

Conclusions/interpretation: Vitamin D status is associated with HbA(1c) and diabetes in cystic fibrosis, particularly in children. The study justifies prospective studies on the proposed role of vitamin D deficiency in the pathophysiology of diabetes mellitus.

Citing Articles

Development and Evaluation of a Pharmacist-Driven Vitamin D Protocol for a Cystic Fibrosis Clinic.

Yett E, Phan H, Mills A, Fleming J, Majure J, Malinowski S J Pediatr Pharmacol Ther. 2022; 27(4):306-311.

PMID: 35558342 PMC: 9088445. DOI: 10.5863/1551-6776-27.4.306.


Vitamin D Status and Risk of Cystic Fibrosis-Related Diabetes: A Retrospective Single Center Cohort Study.

Peng Y, Wu M, Alvarez J, Tangpricha V Nutrients. 2021; 13(11).

PMID: 34836301 PMC: 8619506. DOI: 10.3390/nu13114048.


A Clinician's guide to vitamin D supplementation for patients with cystic fibrosis.

Wood C, Hasan S, Darukhanavala A, Tangpricha V J Clin Transl Endocrinol. 2021; 26:100273.

PMID: 34815946 PMC: 8593649. DOI: 10.1016/j.jcte.2021.100273.


Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D administration.

Alvarez J, Chong E, Walker D, Chandler J, Michalski E, Grossmann R Metabolism. 2017; 70:31-41.

PMID: 28403943 PMC: 5407388. DOI: 10.1016/j.metabol.2017.02.006.


Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Qvist T, Taylor-Robinson D, Waldmann E, Olesen H, Hansen C, Mathiesen I J Cyst Fibros. 2015; 15(3):380-5.

PMID: 26482717 PMC: 4893021. DOI: 10.1016/j.jcf.2015.09.007.


References
1.
Lillegaard I, Andersen L . Validation of a pre-coded food diary with energy expenditure, comparison of under-reporters v. acceptable reporters. Br J Nutr. 2005; 94(6):998-1003. DOI: 10.1079/bjn20051587. View

2.
Jeffery L, Burke F, Mura M, Zheng Y, Qureshi O, Hewison M . 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009; 183(9):5458-67. PMC: 2810518. DOI: 10.4049/jimmunol.0803217. View

3.
Stephenson A, Brotherwood M, Robert R, Atenafu E, Corey M, Tullis E . Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr. 2007; 85(5):1307-11. DOI: 10.1093/ajcn/85.5.1307. View

4.
Timms P, Mannan N, Hitman G, Noonan K, Mills P, Syndercombe-Court D . Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. QJM. 2002; 95(12):787-96. DOI: 10.1093/qjmed/95.12.787. View

5.
Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View